SANDOZ' TAVIST-1 AND TAVIST-D RECOMMENDED FOR Rx-TO-OTC SWITCH APPROVAL: LABELING SHOULD INCLUDE HIGHLIGHTED DROWSINESS WARNING - - FDA ADVISORY CMTE.